Cyclooxygenase-2 and Akt mediate multiple growth-factor-induced epithelial-mesenchymal transition in human hepatocellular carcinoma

J Gastroenterol Hepatol. 2012 Mar;27(3):566-78. doi: 10.1111/j.1440-1746.2011.06980.x.

Abstract

Background and aim: Cancer invasion and metastasis are characterized by epithelial-mesenchymal transition (EMT). Hepatocellular carcinoma (HCC) causes metastasis and significant mortality. Elucidating factors promoting EMT in HCC are necessary to develop effective therapeutic strategies.

Methods: The LH86 cell line was developed in our laboratory from well-differentiated HCC without associated hepatitis or cirrhosis and used as a model to study EMT in HCC. Effects of transforming growth factor β-1, epidermal growth factor, hepatocyte growth factor and basic fibroblast growth factor (bFGF) were examined using morphology, molecular markers, effects on migration and tumorigenicity. The involvement of cyclooxygenase-2 (COX-2) and Akt were examined.

Results: LH86 cells display epithelial morphology. Transforming-growth-factor-β-1-, epidermal-growth-factor-, hepatocyte-growth-factor- and basic-fibroblast-growth-factor-induced mesenchymal changes in them were associated with loss of E-cadherin, albumin, α-1 anti-trypsin expression and increased expression of vimentin, collagen I and fibronectin. There was associated increased migration, tumorigenicity and increased expression of COX-2, prostaglandin E2 (PGE2), Akt and phosphorylated Akt. Inhibition of COX-2 and Akt pathways led to inhibition of characteristics of EMT.

Conclusions: Multiple growth factors induce EMT in HCC. COX-2 and Akt may mediate EMT-associated development and progression of HCC and molecular targeting of COX-2 and Akt may be an effective therapeutic or chemopreventive strategy in advanced and metastatic HCC.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Albumins / genetics
  • Albumins / metabolism
  • Animals
  • Cadherins / genetics
  • Cadherins / metabolism
  • Carcinoma, Hepatocellular / metabolism*
  • Carcinoma, Hepatocellular / pathology
  • Cell Movement / drug effects
  • Cell Transplantation
  • Collagen Type I / metabolism
  • Cyclooxygenase 2 / genetics
  • Cyclooxygenase 2 / metabolism*
  • Dinoprostone / metabolism
  • Epidermal Growth Factor / pharmacology
  • Epithelial-Mesenchymal Transition / drug effects*
  • Fibroblast Growth Factor 2 / pharmacology
  • Fibronectins / metabolism
  • Gene Expression
  • Hepatocyte Growth Factor / pharmacology
  • Humans
  • Mice
  • Oncogene Protein v-akt / genetics
  • Oncogene Protein v-akt / metabolism*
  • RNA, Small Interfering
  • Signal Transduction / drug effects
  • Transforming Growth Factor beta1 / pharmacology
  • Tumor Cells, Cultured
  • Vimentin / metabolism
  • alpha 1-Antitrypsin / genetics
  • alpha 1-Antitrypsin / metabolism

Substances

  • Albumins
  • Cadherins
  • Collagen Type I
  • Fibronectins
  • RNA, Small Interfering
  • Transforming Growth Factor beta1
  • Vimentin
  • alpha 1-Antitrypsin
  • Fibroblast Growth Factor 2
  • Epidermal Growth Factor
  • Hepatocyte Growth Factor
  • Cyclooxygenase 2
  • Oncogene Protein v-akt
  • Dinoprostone